In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates.

CONCLUSIONS: TNP-2092 is highly active against H. pylori and against strains resistant to clarithromycin or levofloxacin. Its antibacterial activity is both concentration- and time-dependent .The antibacterial activity of TNP-2092 appears to be pH-dependent and is more active under neutral pH. TNP-2092 represents a promising new therapy for the treatment of H. pylori infection in primary patients.
PMID: 30044468 [PubMed - in process]

Source: Swiss Medical Weekly - July 23, 2018 Category: General Medicine Authors: Wang B, Zhao Q, Yin W, Yuan Y, Wang X, Wang YH, Wang H, Ye W, Chen S, Guo HL, Xie Y Tags: Swiss Med Wkly Source Type: research